Kinloch Capital’s Carisma Therapeutics CARM Stock Holding History

Kinloch Capital’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$3K	–	79
2020 Q4	$3K	Buy	+100	New	+$2.54K	﹤0.01%	194

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kinloch Capital's CARM Position: Q1 2021 in Review

Kinloch Capital sold out of Carisma Therapeutics (CARM) in Q1 2021, closing a stake of 100 shares — an estimated $3K sold.

Kinloch Capital first reported a position in CARM in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 76 funds tracked by Wall St. Rank hold CARM as of Q1 2021.

Kinloch Capital reported no remaining Carisma Therapeutics position as of Q1 2021 after selling out during the quarter.
Kinloch Capital sold 100 Carisma Therapeutics shares in Q1 2021, an estimated $3K.
Kinloch Capital first reported a position in Carisma Therapeutics in Q4 2020 and held it in 1 quarter.
Kinloch Capital's Carisma Therapeutics position peaked at $3K in Q4 2020.
76 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2021.

Based on Kinloch Capital's 13F filing for Q1 2021, filed 11 May 2021.